Empagliflozin Useful Second-Line for Diabetes vs GlimepirideEmpagliflozin Useful Second-Line for Diabetes vs Glimepiride

The SGLT2 inhibitor empagliflozin provided favorable results at 2 years compared with the sulfonylurea glimepiride when used as second-line therapy after metformin in diabetes. Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news